Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Change of Adviser

August 30, 2024
RNS Number : 2027C Renalytix PLC 30 August 2024     Renalytix plc ("Renalytix" or the "Company")   Change of Adviser   LONDON and NEW YORK , 30 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical

Total Voting Rights

August 30, 2024
RNS Number : 2021C Renalytix PLC 30 August 2024     Renalytix plc ("Renalytix" or the "Company")   Total Voting Rights   LONDON  and  NEW YORK , 30 August 2024  -  Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that at today's date, the Company's total issued share capital is   165,925,513

Nasdaq Grants Listing Extension

August 27, 2024
RNS Number : 8219B Renalytix PLC 27 August 2024   Renalytix plc ("Renalytix" or the "Company")   Nasdaq Grants Listing Extension   Renalytix's American Depositary Shares ("ADSs") will continue trading on the Nasdaq Capital Market effective at the open of trading on August 27, 2024   LONDON and NEW

Appointment of Joint Corporate Broker

August 21, 2024
RNS Number : 1687B Renalytix PLC 21 August 2024   Renalytix plc ("Renalytix" or the "Company")   Appointment of Joint Corporate Broker   LONDON and NEW YORK , 21 August 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on

Termination of Formal Sale Process

August 20, 2024
RNS Number : 9865A Renalytix PLC 20 August 2024   Renalytix plc ("Renalytix" or the "Company")   Termination of Formal Sale Process   LONDON and NEW YORK , 20 August 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 16, 2024
RNS Number : 8107A Polar Capital Holdings PLC 16 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 15, 2024
RNS Number : 6386A Polar Capital Holdings PLC 15 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of

Polar Capital Hldgs - Form 8.3 - RENALYTIX PLC

August 13, 2024
RNS Number : 3080A Polar Capital Holdings PLC 13 August 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

August 1, 2024
RNS Number : 7759Y Stifel Nicolaus Europe Limited 01 August 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

July 30, 2024
RNS Number : 3617Y Stifel Nicolaus Europe Limited 30 July 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of
Displaying 1 - 10 of 452